14 results about "Murine antibody" patented technology

Disclosed are an antibody capable of binding to thymic stromal lymphopoietin and the use thereof. Disclosed are an anti-TSLP antibody, comprising a murine antibody, chimeric antibody and humanized antibody of the light chain and heavy chain variable regions of the anti-TSLP antibody and antigen-binding fragments thereof, or a pharmaceutically acceptable salt or solvent compound thereof, and the use thereof as a drug for treating asthma, especially the use thereof in the preparation of a drug for treating TSLP-positive diseases or conditions.

The application relates to an AI-assisted result interpretation micro-sample detection kit for cutaneous leishmaniasis infection and an antibody detection method, and belongs to the technical field of serological immunodetection. The kit comprises an antibody detection platform for micro-samples, micro-bead probes, a washing solution, an antibody diluent, F594-labeled sheep anti-rat antibodies, positive quality control serum and negative quality control serum; the spherical probes are adopted in the application, the antigen-antibody combination efficiency is improved in space, and the antigen-antibody collision probability is effectively improved. Meanwhile, the micro-beads form a micro-scale mass transfer network in the reaction cavity, fluid mixing is enhanced, the reaction time is shortened, and the overall residence time and consumption of samples and reagents in the microfluidic channel are reduced. The application also introduces an AI-assisted result interpretation system to assist in result interpretation, significantly improves the friendliness and accessibility of the detection process, the classification model based on artificial intelligence has stronger robustness and judgment consistency, and has good market development value and popularization and application prospect.

The present application belongs to the technical field of bioengineering. The present application relates to a recombinant protein, which comprises two dominant antigen epitopes of feline calicivirus (FCV) protein. In order to improve the yield of the recombinant protein in a prokaryotic expression system, the amino acid sequence of the recombinant protein is converted into a corresponding nucleotide sequence by using E. coli preferred codons, the nucleotide sequence is chemically synthesized, and a recombinant expression vector is constructed. The present application also relates to the establishment of a phage library by immunizing mice with the recombinant protein, the screening of a single-chain antibody (scfv) sequence corresponding to the feline calicivirus recombinant protein by panning, the construction of a complete mouse IgG1 antibody sequence expression vector from the obtained scfv sequence, the expression of a monoclonal antibody by instantaneously transferring HEK293F cells, the purification of the monoclonal antibody, and the labeling of europium ions (Eu 3+ ) in the monoclonal antibody, respectively. The optimal monoclonal antibody pairing combination is determined by orthogonal experiments, and the monoclonal antibody can be used for the early diagnosis of upper respiratory tract infection in cats.

The present application provides a monoclonal antibody targeting adenovirus DBP protein, comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the amino acid sequences of HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NOs: 1-3, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 are respectively shown as SEQ ID NOs: 4-6. The monoclonal antibody of the present application can be used for efficient detection of multiple types of HAdV DBP.

The application belongs to the technical field of gene detection, and particularly relates to a colloidal gold detection test strip for HPV18 subtype, a preparation method and application thereof. A nano-antibody 4B10 against HPV18 E7 antigen is added into a colloidal gold solution, and is sealed, centrifuged and resuspended to obtain a nano-antibody-colloidal gold probe; a detection line containing a nano-antibody 1H10 against HPV18 E7 antigen and a quality control line containing a sheep anti-mouse IgG antibody are arranged on a detection film; a sample pad, a binding pad, the detection film and a water absorption pad are assembled to obtain the required colloidal gold detection test strip. Experiments show that the test strip prepared in the application not only realizes rapid and specific detection of the HPV18 E7 antigen, and the detection sensitivity reaches 5 ng / mL, but also exhibits excellent batch consistency and long-term stability, solves the key bottleneck of commercialization of POCT products, and has extremely high industrial value.

Breast cancer is a serious type of cancer that affects many women each year, often leading to death. To choose the right treatment for breast cancer, studying biomarkers is crucial, and one way to do this is by using the immunohistochemical technique (IHC). Biomarkers like Estrogen receptor (ER), progesterone receptor (PR), Ki67, and P53 play a crucial role in determining the prognosis, progression, and response to treatment of breast cancer. Specific monoclonal antibodies against these biomarkers were created by immunizing mice with peptides derived from these proteins. These antibodies were then tested for specificity using ELISA and IHC staining on normal and cancerous tissues, confirming their ability to recognize the receptors. Additionally, the antibodies were evaluated for isotype, affinity constant, and their ability to detect natural antigens in flow cytometry and western blot.

Providing enriched antigen-specific antibodies for analytical and therapeutic use. [Solution] The present invention relates to a method for eliminating interference as described herein, or for enriching or isolating biomarkers, particularly antibodies, before diagnostic testing, or for use for prophylactic or therapeutic purposes, using particles (e.g., fine particles, nanoparticles; magnetic, nonmagnetic) having a surface containing the capture portion described herein. A simple, efficient, and cost-effective method for conditioning biological samples to control and mitigate a number of known sample-specific interferences that can result in erroneous test results and increased risks to patient safety, such as heterophilic antibodies in patients treated with monoclonal mouse antibodies or patients who have received them for diagnostic purposes, is described herein.

The application relates to a preparation and application of a chimeric antigen receptor targeting BCMA. The immunogenicity of scFv is significantly reduced by humanizing the mouse-derived antibody, and the human anti-mouse antibody (HAMA) reaction can be reduced, and the persistence and safety of CAR-T cells in the patient body can be improved. The affinity (KD approximately 1.46E-07 M) of the preferred scFv (such as D12.u21) obtained by the application to BCMA is reduced by about 10,000 times compared with that of a commercial high-affinity scFv (C11D5.3, KD approximately 1.09E-11 M). The "medium-low" affinity characteristic aims to balance the activation strength of CAR-T cells and avoid T cell exhaustion caused by excessive activation. Although the affinity is greatly reduced, the CAR-T cells expressing the preferred scFv (D12.u21) of the application show better killing effect than the high-affinity control (C11D5) CAR-T cells in in-vitro experiments. Under a higher target ratio, the killing efficiency and IFN-gamma cytokine secretion level of the CAR-T cells are both significantly higher, indicating that the CAR-T cells have stronger effector function and activation potential.

This invention belongs to the fields of biomedicine and in vitro diagnostics, specifically relating to a specific antibody against porcine epidemic diarrhea virus (PEDV), a nucleic acid molecule, a plasmid vector combination, and a eukaryotic cell expression vector. The amino acid sequence of the specific antibody of this invention consists of two dominant antigenic epitopes of the PEDV N protein tandemly. Using E. coli-preferred codons, the amino acid sequence of this recombinant protein is converted into the corresponding nucleotide sequence, thereby increasing the expression level of the recombinant protein in E. coli. This invention also involves immunizing mice with this recombinant protein, sorting B lymphocytes that specifically bind to the recombinant protein using flow cytometry, amplifying the heavy and light chain variable regions of the B lymphocyte antibody using single-cell PCR, constructing a complete mouse IgG antibody sequence recombinant expression vector from the obtained sequence, expressing the monoclonal antibody by transiently transfecting HEK293F cells, purifying the monoclonal antibody and labeling it with colloidal gold particles, and determining the optimal monoclonal antibody pairing combination through orthogonal experiments.

The present invention belongs to the field of biomedicine. Disclosed in the present invention are preparation of an antibody capable of detecting multi-subtype KPC and the use of a kit thereof. Provided in the present invention are a kit for detecting common subtypes of KPC and the use thereof. Murine antibodies are prepared by means of the conservative antigen epitope immunization of each subtype of KPC, and in-vitro screening and pairing are performed in various ways so as to obtain an antibody pair with good specificity and strong affinity and which is capable of binding to multiple subtypes. The two antibodies can achieve a titer of 1,000,000 or more, and the amino acid sequences of a heavy chain variable region and a light chain variable region thereof are obtained by means of sequencing, thus rapid and stable expression can be achieved after recombination. In the present invention, the product development for carbapenem KPC detection based on an immunochromatography platform has the advantages of high sensitivity, good specificity, good stability, being able to cover multiple prevalent KPC subtypes, and rapid and convenient detection, and provides notable assistance in terms of clinical auxiliary diagnosis and medication guidance.

This invention relates to the field of biodetection technology and discloses a method for preparing a time-resolved fluorescent immunochromatographic test strip for detecting difenoconazole in strawberries, comprising the following steps: S1, preparation of difenoconazole hapten; S2, preparation of difenoconazole antibody; S3, preparation of difenoconazole antibody-time-resolved fluorescent microspheres; S4, preparation of fluorescent microsphere pad: uniformly spraying difenoconazole antibody-time-resolved fluorescent microspheres onto a polyester fiber layer; S5, preparation of reaction membrane: coating a nitrocellulose membrane with a difenoconazole-coating antigen and goat anti-mouse IgG antibody to form a detection line and a control line, respectively; S6, test strip assembly. The test strip prepared by this invention has high sensitivity for detecting difenoconazole, and can detect low concentrations of difenoconazole in strawberries; it can specifically detect difenoconazole in strawberries with high accuracy; at the same time, it has good stability and can be stored for more than 12 months.

Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and / or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.

This disclosure provides anti-GPC3 antibodies, including murine antibodies, humanized antibodies, and those with further optimized CDR sequences. The newly disclosed antibodies exhibited higher cell-based binding efficiency than the leading anti-GPC3 antibody candidate under clinical development.

The present application provides a set of monoclonal antibody pairs targeting adenovirus DBP protein, which consists of a capture antibody and a detection antibody, both of which comprise a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein: the capture antibody is monoclonal antibody 19E3; the detection antibody is selected from monoclonal antibody 96-10D8, 95-2B7, 96-2C10, 96-8E10, 96-13D5 or 96-2B10. The monoclonal antibody pairs of the present application can be used for efficient detection of multiple types of HAdV DBP.